ROS1 Gene Mutation Withdrawn Phase 2 Trials for Brigatinib (DB12267)

IndicationStatusPhase
DBCOND0082893 (ROS1 Gene Mutation)Withdrawn2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03868423Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid CancersTreatment